Onconetix, Inc. Ratios | P/E, ROE & Valuation

On the Key Ratios page for Onconetix, Inc. (ONCO), the latest P/E of -0.1 frames valuation, while ROE -91.95% and ROIC -59.84% indicates profitability and capital efficiency. Together with the current ratio of 2.21 and debt-to-equity 0.01, these signals help you judge whether valuation is supported by fundamentals across the historical rows.

Financial Performance Ratios

ONCO Historical Per Share Metrics

7 years
Metric (FY)TTM202420232022202120202019
Revenue per Share$0.29$78.15$0.14$0.00$0.00$0.00$0.00
Net Income per Share$-4.55$-1817.06$-87.45$-1.09$-0.31$-0.14$-0.07
Operating Cash Flow per Share$-4.60$-324.95$-31.75$-0.71$-0.19$-0.16$-0.07
Free Cash Flow per Share$-4.60$-325.83$-31.88$-0.71$-0.19$-0.16$-0.08
Cash per Share$2.65$20.02$10.65$2.10$0.18$0.39$0.55
Book Value per Share$6.01$297.54$150.40$1.82$0.13$0.43$0.54
Tangible Book Value per Share$1.72$-539.89$-39.16$1.82$0.13$0.43$0.54
Interest Debt per Share$0.22$336.07$24.85$0.00$0.00$0.00$0.00
CAPEX per Share$0.00$0.88$0.13$0.00$0.00$0.00$0.00

ONCO Historical Valuation Ratios

7 years
Metric (FY)TTM202420232022202120202019
Price to Earnings (P/E)-0.08-0.03-7.7-3419.96-623274.41-1348101.33-2623437.02
Price to Book (P/B)0.110.184.912049.991472397.82455502.11359469.62
Price to Sales (P/S)3.740.694925.750000
Enterprise Value to EBITDA0.34-0.18-7.99-3419.76-624166.99-1350679.29-2625259.87
EV to Sales-5.174.175018.210000
EV to Operating Cash Flow0.32-1-21.6-5273.04-1041922.72-1246280.89-2613220.51
EV to Free Cash Flow0.32-1-21.52-5267.39-1040943-1237844.19-2599046.06
Enterprise Value$-3.34M$10.53M$293.39M$45.87B$2129.93B$2156.24B$2156.24B

ONCO Historical Profitability Ratios

7 years
Metric (FY)TTM202420232022202120202019
Return on Equity (ROE)-91.95%-610.69%-63.80%-59.94%-236.24%-33.79%-13.70%
Return on Invested Capital (ROIC)-59.84%-286.99%-44.97%-60.22%-236.24%-34.20%-14.66%
Return on Tangible Assets-149.76%-5182.02%-581.71%-51.01%-110.78%-33.24%-13.52%
Earnings Yield-674.22%-3393.20%-12.99%-0.03%-0.00%-0.00%-0.00%
Free Cash Flow Yield-426.50%-608.46%-4.74%-0.02%-0.00%-0.00%-0.00%
Dividend Yield0.00%11.93%0.00%0.00%0.00%0.00%0.00%

ONCO Historical Liquidity & Financial Strength

7 years
Metric (FY)TTM202420232022202120202019
Current Ratio2.210.050.346.691.8866.9479.98
Interest Coverage-26.28-40.13-53.650000
Income Quality1.010.180.360.650.61.081
Debt to Equity0.010.980.170000
Debt to Assets1.14%33.52%11.38%0.00%0.00%0.00%0.00%
Net Debt to EBITDA0.58-0.15-0.151.920.572.77.37

ONCO Historical Efficiency Ratios

7 years
Metric (FY)TTM202420232022202120202019
Receivables Turnover274.726.210.390000
Payables Turnover0.070.390.2200.010.040.03
Inventory Turnover0.622.933.2600.0100
Days Sales Outstanding1.3313.93934.780000
Days Payables Outstanding5319941.081630.1281049.0343486.888201.5111706.12
Days of Inventory on Hand606.7515.92112.07056552.3100

ONCO Historical Market Metrics

7 years
Metric (FY)TTM202420232022202120202019
Enterprise Value to EBITDA0.34-0.18-7.99-3419.76-624166.99-1350679.29-2625259.87
Market Cap$2.42M$1.73M$287.98M$45.90B$2129.94B$2156.24B$2156.24B
Enterprise Value$-3.34M$10.53M$293.39M$45.87B$2129.93B$2156.24B$2156.24B
Dividend Yield0.00%11.93%0.00%0.00%0.00%0.00%0.00%
Payout Ratio0.00%-0.35%0.00%0.00%0.00%0.00%0.00%

Frequently Asked Questions

How does Onconetix, Inc.’s P/E ratio compare with its history?

On this page, you can use the latest P/E (from the Key Ratios table) as your starting point and compare it to the company's multi-year P/E range in the historical rows. When the current P/E sits near its historical average, the multiple is close to that range. Look at trend direction in profitability and cash-flow rows, plus liquidity and leverage, rather than treating the P/E in isolation.

What is Onconetix, Inc. market cap?

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $2.42M. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

How does Onconetix, Inc.’s P/E compare with its industry?

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Onconetix, Inc.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

How does Onconetix, Inc. compare to its competitors in key financial ratios?

The fastest way to compare Onconetix, Inc. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Onconetix, Inc. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

What do Onconetix, Inc.'s liquidity and leverage ratios show?

Liquidity and leverage figures on this page are published ratios, not a verdict that Onconetix, Inc. is financially strong. Current ratio is about 2.21, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about -26.28, implying less buffer for servicing interest costs. Debt-to-equity is about 0.01, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

What do Onconetix, Inc.'s financial ratios say about its future growth?

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Onconetix, Inc. is sustaining strong returns (for example ROE at -91.95% and ROIC at -59.84%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.